<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000393543">
  <TermName>rebeccamycin analog</TermName>
  <TermPronunciation>(reh-BEH-kuh-MY-sin A-nuh-log)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called antitumor antibiotics and topoisomerase inhibitors. Also called NSC 655649.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000713403" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;rebeccamycin analog&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000713402" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;análogo de la rebecamicina&quot;" language="es" id="_4"/>
  <SpanishTermName>análogo de la rebecamicina</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Es un tipo de antibiótico antitumoral y de inhibidor de la topoisomerasa. También se llama NSC 655649.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2004-11-22</DateFirstPublished>
  <DateLastModified>2006-11-07</DateLastModified>
</GlossaryTerm>
